Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report issued on Sunday. The brokerage issued a sell rating on the stock.

A number of other brokerages also recently issued reports on SYRS. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Syros Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of NASDAQ:SYRS opened at $0.21 on Friday. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 1.97. The company has a 50-day moving average price of $1.31 and a 200-day moving average price of $3.00. The company has a market cap of $5.61 million, a price-to-earnings ratio of -0.07 and a beta of 1.33. Syros Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the business earned ($1.35) earnings per share. As a group, equities analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Buying and Selling

In related news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 12.26% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock valued at $4,965,000 after acquiring an additional 163,234 shares in the last quarter. Acadian Asset Management LLC increased its stake in Syros Pharmaceuticals by 101.5% during the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares in the last quarter. Certuity LLC purchased a new position in Syros Pharmaceuticals in the second quarter worth about $109,000. GSA Capital Partners LLP purchased a new position in Syros Pharmaceuticals in the third quarter worth about $34,000. Finally, Exome Asset Management LLC lifted its stake in shares of Syros Pharmaceuticals by 87.6% in the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after buying an additional 139,400 shares in the last quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.